EUVIMEDEUVIMED entdecken
Crossref

Myocardial Responses to Eplontersen in Transthyretin Amyloid Cardiomyopathy: The CARDIO-TTRansform CMR study

Yousuf Razvi iD, Scott D Solomon iD, Sarah A M Cuddy iD, Lucia Venneri iD, Ana Martinez-Naharro iD, Francesco Cappelli iD, Alberto Cipriani iD, Pablo Garcia-Pavia iD, Ahmad Masri iD, Awais Sheikh iD, Noemi Ramos-Lopez iD, Priya Sekar und 14 weitere

Circulation · 09.11.2026

DOI: 10.1161/circulationaha.126.083732 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, online erschienen am 09.11.2026. Verfasst von Yousuf Razvi und 25 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, UK. Gefördert von: AstraZeneca, Ionis Pharmaceuticals.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transthyretin-lowering therapies target the underlying cause of transthyretin amyloid cardiomyopathy (ATTR-CM), but their effects on myocardial amyloid burden and cardiac remodelling remain incompletely characterized. We evaluated the myocardial effects of sustained transthyretin suppression with eplontersen using serial multiparametric cardiovascular magnetic resonance (CMR).

Methods

This CMR study was a pre-specified, international, prospective study embedded within the randomized, placebo-controlled phase 3 CARDIO-TTRansform trial. Participants underwent CMR at baseline and planned assessments at weeks 25, 49, 97, and 140. The primary imaging analysis evaluated longitudinal changes in CMR parameters using mixed models for repeated measures. Myocardial amyloid regression and progression were defined as ≥5 percentage-point decreases and increases in extracellular volume (ECV), respectively. All other patients were considered stable.

Results

We enrolled 120 participants with baseline and ≥1 follow-up CMR assessment (eplontersen, n=58; placebo, n=62; mean age, 76.7±6.5 years; 95% male; baseline stabilizer, 12.5%). At week 140 eplontersen resulted in lower ECV, compared with placebo (least-squares mean difference [95% CI], –6.7 percentage points [ –8.7 to –4.7]; P

Autor:innen und Institutionen

  • National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, UK.
  • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
  • Tuscan Regional Amyloidosis Center, Department of Clinical and Experimental Medicine, University Hospital Careggi, Florence, Italy.
  • Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.
  • Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Division of Cardiovascular Medicine, Oregon Health and Science University, Portland, OR.

ORCID-Profile: Yousuf Razvi, Scott D Solomon, Sarah A M Cuddy, Lucia Venneri, Ana Martinez-Naharro, Francesco Cappelli, Alberto Cipriani, Pablo Garcia-Pavia, Ahmad Masri, Awais Sheikh, Noemi Ramos-Lopez, Brian Claggett, Peter Kellman, Farooq H Sheikh, Justin L Grodin, Charlotte Manisty, George D Thornton, James C Moon, Mathew S Maurer, Jersey Chen, Sotirios Tsimikas, Julian D Gillmore, Marianna Fontana

Förderung

  • AstraZeneca
  • Ionis Pharmaceuticals

Zitieren

APA

Razvi, Y., Solomon, S. D., Cuddy, S. A. M., Venneri, L., Martinez-Naharro, A., Cappelli, F., Cipriani, A., Garcia-Pavia, P., Masri, A., Sheikh, A., Ramos-Lopez, N., Sekar, P., Conrad, T., Claggett, B., Kellman, P., Sheikh, F. H., Grodin, J. L., Manisty, C., Thornton, G. D., …, & Fontana, M. (2026). Myocardial Responses to Eplontersen in Transthyretin Amyloid Cardiomyopathy: The CARDIO-TTRansform CMR study. Circulation. https://doi.org/10.1161/circulationaha.126.083732

Vancouver

Razvi Y, Solomon SD, Cuddy SAM, Venneri L, Martinez-Naharro A, Cappelli F, et al. Myocardial Responses to Eplontersen in Transthyretin Amyloid Cardiomyopathy: The CARDIO-TTRansform CMR study. Circulation. 2026. doi:10.1161/circulationaha.126.083732

BibTeX
@article{Razvi2026,
  author = {Razvi, Yousuf and Solomon, Scott D and Cuddy, Sarah A M and Venneri, Lucia and Martinez-Naharro, Ana and Cappelli, Francesco and Cipriani, Alberto and Garcia-Pavia, Pablo and Masri, Ahmad and Sheikh, Awais and Ramos-Lopez, Noemi and Sekar, Priya and Conrad, Tom and Claggett, Brian and Kellman, Peter and Sheikh, Farooq H and Grodin, Justin L and Manisty, Charlotte and Thornton, George D and Moon, James C and Maurer, Mathew S and Angeli, Franca S and Chen, Jersey and Tsimikas, Sotirios and Gillmore, Julian D and Fontana, Marianna},
  title = {Myocardial Responses to Eplontersen in Transthyretin Amyloid Cardiomyopathy: The CARDIO-TTRansform CMR study},
  journal = {Circulation},
  year = {2026},
  doi = {10.1161/circulationaha.126.083732}
}
Kostenlos starten →